Galapagos increases share capital through warrant exercises
April 03 2016 - 4:29PM
Galapagos NV (Euronext & NASDAQ: GLPG) announces a share
capital increase arising from warrant exercises.
Galapagos issued 131,695 new ordinary shares on
1 April 2016, for a total capital increase (including
issuance premium) of €1,409,307.45.
Pursuant to the rules of the warrant exercise
program of Galapagos' Executive Committee adopted in 2013,
Executive Committee members automatically are committed to exercise
a minimum number of warrants, subject to certain conditions.
Accordingly, CEO Onno van de Stolpe exercised 10,000 warrants; two
other Executive Committee members exercised an aggregate number of
5,000 warrants. In addition to Onno van de Stolpe, three
other Board members exercised an aggregate of 45,470 warrants.
Raj Parekh and Harrold van Barlingen exercised warrants to
hold them as shares, increasing their shareholdings to 31,250 and
15,620 shares, respectively.
In accordance with Belgian transparency
legislation[1], Galapagos notes that its total share capital
currently amounts to €248,632,657.08; the total number of
securities conferring voting rights is 45,968,738, which is also
the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
3,152,997, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does
not have any convertible bonds or shares without voting rights
outstanding. About Galapagos Galapagos (Euronext &
NASDAQ: GLPG) is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises three Phase 2,
three Phase 1, five pre-clinical, and 20 discovery studies in
cystic fibrosis, inflammation, fibrosis, osteoarthritis and other
indications. We have discovered and developed filgotinib: in
collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the
world. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 440 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information at
www.glpg.com.
Contacts
Investors:
Media: Elizabeth
Goodwin Evelyn
Fox VP IR & Corporate
Communications Director
Communications Tel: +1 781 460
1784
Tel: +31 6 53 591 999 E-mail:
ir@glpg.com E-mail: communications@glpg.com
Forward-looking statements This release may contain
forward-looking statements. Galapagos cautions the reader that
forward-looking statements are not guarantees of future
performance. Forward-looking statements involve known and
unknown risks, uncertainties and other factors which might cause
the actual results, financial condition and liquidity, performance
or achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity,
and the development of the industry in which it operates are
consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods. A
list and description of these risks, uncertainties and other risks
can be found in Galapagos' Securities and Exchange Commission (SEC)
filings and reports, including in Galapagos' most recent annual
report on Form 20 F filed with the SEC and other filings and
reports filed by Galapagos with the SEC. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
[1]Belgian Act of 2 May 2007 on the disclosure of major
shareholdings in issuers whose shares are admitted to trading on a
regulated market
HUG#1999857
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024